Source: Eur Respir J 2009; 33: 1220-1222
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Luisetti M., Rodi G., Perotti C., Campo I., Mariani F., Pozzi E., Trapnell B. C.. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1220-1222

Member's Comments

No comment yet.

Related content which might interest you: Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis Source: Eur Respir J 2006; 27: 585-593 Year: 2006 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Alveolar lipoproteinosis syndromes Source: Eur Respir Mon 2011; 54: 171-186 Year: 2011 Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Efficacy of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) in a Japanese female patient with pulmonary alveolar proteinosis (PAP) Source: Eur Respir J 2001; 18: Suppl. 33, 221s Year: 2001 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Inhaled granulocyte–macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis Source: Eur Respir J, 51 (4) 1702127; 10.1183/13993003.02127-2017 Year: 2018 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Association of genetic variations in the CSF2 and CSF3 genes with lung function in smoking-induced COPD Source: Eur Respir J 2008; 32: 25-34 Year: 2008 Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Insulin-like growth factor-1 in idiopathic pulmonary fibrosis bronchoalveolar lavage fluid protects lung fibroblasts from apoptosis Source: Eur Respir J 2001; 18: Suppl. 33, 358s Year: 2001